专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012046061A2 CLOSTRIDIUM DIFFICILE ANTIGENS 审中-公开
标题翻译：胶原蛋白抗体
公开(公告)号：WO2012046061A2
公开(公告)日：2012-04-12
申请号：PCT/GB2011/051910
申请日：2011-10-05
申请人： HEALTH PROTECTION AGENCY , MICROPHARM LIMITED , SHONE, Clifford , ROBERTS, April , AHERN, Helen , MAYNARD-SMITH, Michael , LANDON, John
发明人： SHONE, Clifford , ROBERTS, April , AHERN, Helen , MAYNARD-SMITH, Michael , LANDON, John
IPC分类号： C07K14/435
CPC分类号： A61K39/08 , A61K38/164 , A61K39/40 , A61K2039/505 , C07K14/33 , C07K16/1282 , C07K2317/76 , C07K2319/00
摘要： The present invention relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C. difficile Toxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a C. difficile Toxin B. Also provided is the use of said antigens for the prevention/ treatment/ suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/ treatment/ suppression of CDI.
摘要翻译：本发明涉及基于由第一氨基酸序列和第二氨基酸序列组成或包含第一氨基酸序列和第二氨基酸序列的融合蛋白的重组艰难梭菌抗原，其中：a）第一个氨基酸序列由具有与艰难梭菌毒素A序列的残基500-1850和艰难梭菌毒素B序列的残基1500-1851组成的氨基酸序列具有至少80％的序列同一性; 和b）第二个氨基酸序列由氨基酸序列提供，该氨基酸序列与由位于艰难梭菌毒素A序列的氨基酸残基1851-2710内的长重复单元组成的氨基酸序列具有至少80％的序列同一性或艰难梭菌毒素B序列的氨基酸残基1852-2366内; 尽管条件是融合蛋白不是包含艰难梭菌毒素A的氨基酸残基543-2710的多肽，条件是融合蛋白不是包含艰难梭菌的氨基酸残基543-2366的多肽毒素B.还提供了所述抗原用于预防/治疗/抑制艰难梭菌感染（CDI）的用途，以及产生所述抗原的方法，产生结合所述抗原的抗体的方法和所述抗体的使用用于预防/治疗/抑制CDI。

2. 发明申请

WO2011067616A1 THERAPIES FOR PREVENTING OR SUPPRESSING CLOSTRIDIUM DIFFICILE INFECTION 审中-公开
标题翻译：用于预防或抑制闭锁性感染的治疗方法
公开(公告)号：WO2011067616A1
公开(公告)日：2011-06-09
申请号：PCT/GB2010/052035
申请日：2010-12-06
申请人： HEALTH PROTECTION AGENCY , MICROPHARM LIMITED , SHONE, Clifford , ROBERTS, April , LANDON, John
发明人： SHONE, Clifford , ROBERTS, April , LANDON, John
IPC分类号： A61K39/40 , C07K16/12
CPC分类号： C07K16/1282 , A61K2039/505 , A61K2039/542 , C07K2317/20
摘要： The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin, and wherein said prevention or treatment is by oral delivery of the antibody composition. Also provided is a pharmaceutical composition of ovine antibodies for oral delivery, which further comprises one or more means for protecting the antibodies from trypsin and/ or chymotrypsin and/ or stomach acid.
摘要翻译：本发明提供了一种抗体组合物，其包含用于预防或治疗艰难梭菌感染的羊抗体，其中所述抗体与艰难梭菌毒素结合，并且其中所述预防或治疗是通过口服递送所述抗体组合物。还提供了用于口服递送的羊抗体的药物组合物，其还包含用于保护来自胰蛋白酶和/或胰凝乳蛋白酶和/或胃酸的抗体的一种或多种方法。

3. 发明申请

WO2010094970A1 ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS 审中-公开
标题翻译：抗菌药物对毒死蜱毒素的抗体
公开(公告)号：WO2010094970A1
公开(公告)日：2010-08-26
申请号：PCT/GB2010/050288
申请日：2010-02-19
申请人： HEALTH PROTECTION AGENCY , MICROPHARM LIMITED , SHONE, Clifford , LANDON, John
发明人： SHONE, Clifford , LANDON, John
IPC分类号： A61K39/40 , C07K16/12
CPC分类号： C07K16/1282 , A61K2039/505 , C07K2317/20
摘要： The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin.
摘要翻译：本发明提供了一种包含羊抗体的抗体组合物，其用于预防或治疗艰难梭菌感染，其中所述抗体结合艰难梭菌毒素。

4. 发明申请

WO2006013360A1 FREEZE-DRYING APPARATUS 审中-公开
标题翻译：冷冻干燥装置
公开(公告)号：WO2006013360A1
公开(公告)日：2006-02-09
申请号：PCT/GB2005/003041
申请日：2005-08-03
申请人： MICROPHARM LIMITED , LANDON, John
发明人： LANDON, John
IPC分类号： F26B5/06
CPC分类号： F26B5/06
摘要： A method of freeze-drying a product comprising the steps of: a) placing a closeable vial (1) containing the product in a container comprising: i) a tray (2); ii) a lid (7); and iii) a membrane (31); wherein the lid (7) and tray (2) co-operate to form a hermetic seal therebetween and the lid (7) can move relative to the tray (2) to effect closure of the closeable vials (1); b) freeze-drying the product; and c) moving the lid (7) and tray (2) relative to one another to effect closure of the closeable vials (1). Containers for use in the method are also provided.
摘要翻译：一种冷冻干燥产品的方法，包括以下步骤：a）将容纳产品的可关闭小瓶（1）放置在容器中，该容器包括：i）托盘（2）; ii）盖（7）; 和iii）膜（31）; 其中所述盖（7）和托盘（2）协同操作以在其间形成气密密封，并且所述盖（7）可相对于所述托盘（2）移动以实现所述可关闭小瓶（1）的关闭。 b）冷冻干燥产品; 和c）相对于彼此移动盖（7）和托盘（2）以实现可关闭小瓶（1）的关闭。还提供了用于该方法的容器。

5. 发明申请

WO1994029348A2 PRODUCTION OF ANTIBODY FRAGMENTS 审中-公开
标题翻译：生产抗体片段
公开(公告)号：WO1994029348A2
公开(公告)日：1994-12-22
申请号：PCT/GB1994001210
申请日：1994-06-03
申请人： THERAPEUTIC ANTIBODIES INC. , LANDON, John
发明人： THERAPEUTIC ANTIBODIES INC.
IPC分类号： C07K15/00
CPC分类号： C12N9/50 , A61K38/00 , C07K16/065 , C07K16/241 , C07K16/44 , C07K2317/55
摘要： A method of preparing polyclonal immunoglobin Fab fragments comprising cleaving immunoglobulin molecules, characterised in that the said cleavage is carried out on immunoglobulins in blood, serum or plasma in a closed, sterile environment.
摘要翻译：制备包含切割免疫球蛋白分子的多克隆免疫球蛋白Fab片段的方法，其特征在于所述切割在封闭的无菌环境中在血液，血清或血浆中的免疫球蛋白上进行。

6. 发明申请

WO1994029347A1 ANTIBODY FRAGMENTS IN THERAPY 审中-公开
标题翻译：抗生素片段治疗
公开(公告)号：WO1994029347A1
公开(公告)日：1994-12-22
申请号：PCT/GB1994001209
申请日：1994-06-03
申请人： THERAPEUTIC ANTIBODIES INC. , LANDON, John
发明人： THERAPEUTIC ANTIBODIES INC.
IPC分类号： C07K15/00
CPC分类号： C12N9/50 , A61K38/00 , C07K16/065 , C07K16/241 , C07K16/44 , C07K2317/55
摘要： A method of neutralising TNF alpha in a patient benifiting from such neutralising, comprising administering to the patient IgG Fab fragment reactive towards TNF alpha . Suitably, the patient is suffering from septic shock or from the symptoms of septic shock. It is preferred if the Fab fragment is derived from polyclonal IgG.
摘要翻译：一种中和TNFα的方法，所述方法包括向患者施用对TNFα具有反应性的IgG Fab片段。适当地，患者患有脓毒性休克或脓毒性休克症状。 Fab片段优选来自多克隆IgG。

7. 发明申请

WO2012046061A3 CLOSTRIDIUM DIFFICILE ANTIGENS 审中-公开
标题翻译：细菌抗生素
公开(公告)号：WO2012046061A3
公开(公告)日：2012-12-20
申请号：PCT/GB2011051910
申请日：2011-10-05
申请人： HEALTH PROT AGENCY , MICROPHARM LTD , SHONE CLIFFORD , ROBERTS APRIL , AHERN HELEN , MAYNARD-SMITH MICHAEL , LANDON JOHN
发明人： SHONE CLIFFORD , ROBERTS APRIL , AHERN HELEN , MAYNARD-SMITH MICHAEL , LANDON JOHN
IPC分类号： C07K14/33 , A61K39/08 , C07K16/12
CPC分类号： A61K39/08 , A61K38/164 , A61K39/40 , A61K2039/505 , C07K14/33 , C07K16/1282 , C07K2317/76 , C07K2319/00
摘要： The present invention relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C. difficile Toxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a C. difficile Toxin B. Also provided is the use of said antigens for the prevention/ treatment/ suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/ treatment/ suppression of CDI.
摘要翻译：本发明涉及基于融合蛋白的重组艰难梭菌抗原，所述融合蛋白由第一氨基酸序列和第二氨基酸序列组成，或者包含第一氨基酸序列和第二氨基酸序列，其中：a）第一氨基酸序列由氨基酸序列提供，与由艰难梭菌毒素A序列的残基500-1850或艰难梭菌毒素B序列的残基1500-1851组成的氨基酸序列具有至少80％的序列同一性; 和b）第二氨基酸序列由与位于艰难梭菌毒素A序列的氨基酸残基1851-2710内的长重复单元组成的氨基酸序列具有至少80％序列同一性的氨基酸序列提供或在艰难梭菌毒素B序列的氨基酸残基1852-2366内; 尽管附带条件是融合蛋白不是包含艰难梭菌毒素A的氨基酸残基543-2710的多肽，并且附带条件是该融合蛋白不是包含艰难梭菌的氨基酸残基543-2366的多肽毒素B.还提供了所述抗原用于预防/治疗/抑制艰难梭菌感染（CDI）的用途，以及用于产生所述抗原的方法，用于产生结合所述抗原的抗体的方法以及所述抗体用于预防/治疗/抑制CDI。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式